Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Can Low LSD Doses Address Alzheimer’s Disease?

Eleusis Is Investigating Anti-Inflammatory Properties Of Psychedelics

Executive Summary

The CEO of Eleusis tells Scrip how the privately held biotech plans to progress low-dose lysergic acid diethylamide (LSD) to both prevent and treat Alzheimer’s

You may also be interested in...



Can COMPASS Bring Psilocybin’s ‘Magic’ To Depression?

COMPASS is testing a synthetic form of psilocybin, the active “magic mushroom” ingredient, in long-term depression patients, and thinks the capsule can be approved by 2025, its co-founder tells Scrip.

AstraZeneca Pledges To Become Carbon-Negative By 2030

AstraZeneca has vowed to slash its carbon emissions to zero by 2025 and ensure its entire value chain is carbon negative by 2030. It will spend up to $1bn to do so.

Novo Executive Calls For ‘Real AMR Action’ In Davos

The Novo Nordisk Foundation is sponsoring a panel at Davos this week on finding solutions to the global crisis on antimicrobial resistance – and hopes world leaders will listen.

Topics

UsernamePublicRestriction

Register

SC141377

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel